Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera ...

Tokyo's benchmark Nikkei 225 index has dipped more than 4% and most other markets in Asia also sank after a retreat on Wall ...

Novo launched a rival bid to acquire American obesity biotech firm Metsera last week, superseding an offer for the firm from ...

Stocks fell on Wall Street, pulled down by losses in the same big tech companies that have been the main drivers of the market’s rally so far this year. The S&P 500 slid 1.2% Tuesday. The Dow Jones ...

The bidding war over biotechnology company Metsera (MTSR) has intensified, drawing fierce competition from pharmaceutical ...

NEW YORK (AP) — Stocks fell on Wall Street Tuesday, pulled down by losses in the same big tech companies that have been the ...

Pfizer’s buyout bid for Metsera was deemed inferior to the latest bid from Novo Nordisk, putting the original agreement in ...

Pfizer CEO Albert Bourla called Novo Nordisk's bid for obesity drug developer Metsera an "illegal...end-run around antitrust laws." ...

The revised bids are the latest unusual twist in the fight between big drugmakers over drug developer Metsera.

The Danish company’s latest offer is more than 30% about what Pfizer initially agreed to pay, not counting potential ...

The battle for control of a promising obesity drug maker has intensified, with one pharmaceutical giant upping its bid to $10 ...

The obesity drug developer has declared a new proposal from Novo “superior” to Pfizer’s original bid as well as an updated ...